(4S,5R)-4,5-bis-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-ylcarbonyl chloride | 871737-78-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (4S,5R)-4,5-bis-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-ylcarbonyl chloride
• 英文别名: (4S,5R)-4,5-bis-(4-chloro-phenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl chloride；(4S,5R)-4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl chloride
• CAS: 871737-78-9
• 化学式: C₂₆H₂₃Cl₃N₂O₃
• 分子量: 517.839
• InChiKey: LJZAWVSKNPEWCI-BJKOFHAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  51.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-乙酰乙醇胺 、 (4S,5R)-4,5-bis-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-ylcarbonyl chloride 以 二氯甲烷 为溶剂， 反应 0.25h， 生成 2-acetamidoethyl 4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazole-1-carboxylate
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of imidazoline derivatives as p53–MDM2 binding inhibitors

  摘要：

  Three series of novel imidazoline derivatives were designed, synthesized, and evaluated for their p53-MDM2 binding inhibitory activities, and anti-proliferation activities against PC3, A549, KB, and HCT116 cancer cell lines. Five of the tested compounds showed enhanced p53-MDM2 binding inhibitory potency and anti-proliferation activities in comparison with that of Nutlin-1. Flow cytometric analysis indicated that compound 7c, one of the most potent p53-MDM2 binding inhibitors with a K(i) value of 0.6 mu M, showed its ability to arrest cell cycle progression. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.07.050
• 作为产物：
  描述：

  (1R,2S)-1,2-bis(4-chlorophenyl)ethane-1,2-diamine 在 N-溴代丁二酰亚胺(NBS) 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.75h， 生成 (4S,5R)-4,5-bis-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-ylcarbonyl chloride
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of imidazoline derivatives as p53–MDM2 binding inhibitors

  摘要：

  Three series of novel imidazoline derivatives were designed, synthesized, and evaluated for their p53-MDM2 binding inhibitory activities, and anti-proliferation activities against PC3, A549, KB, and HCT116 cancer cell lines. Five of the tested compounds showed enhanced p53-MDM2 binding inhibitory potency and anti-proliferation activities in comparison with that of Nutlin-1. Flow cytometric analysis indicated that compound 7c, one of the most potent p53-MDM2 binding inhibitors with a K(i) value of 0.6 mu M, showed its ability to arrest cell cycle progression. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.07.050

文献信息

• [EN] NOVEL CIS-IMIDAZOLINES<br/>[FR] NOUVELLES CIS-IMIDAZOLINES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005123691A1

  公开（公告）日：2005-12-29

  The present invention relates to compounds of the formula (I), and the pharmaceutically acceptable salts and esters thereof, a process for their manufacture, medicaments containing them as well as the use of these compounds as pharmaceutically active agents. The compounds show antiproliferative activity and may be especially useful for the treatment of cancer.

  本发明涉及式(I)的化合物，以及其药用可接受的盐和酯，其制备方法，含有它们的药物，以及将这些化合物用作药用活性剂的用途。这些化合物显示抗增殖活性，可能特别适用于癌症的治疗。
• CIS-imidazolines
  申请人：Haley Jay Gregory

  公开号：US20050282803A1

  公开（公告）日：2005-12-22

  The present invention relates to compounds of the formula and the pharmaceutically acceptable salts and esters thereof, a process for their manufacture, medicaments containing them as well as the use of these compounds as pharmaceutically active agents. The compounds show antiproliferative activity and may be especially useful for the treatment of cancer.

  本发明涉及以下公式的化合物及其药学上可接受的盐和酯，其制备过程，含有它们的药物以及将这些化合物用作药物活性剂的用途。这些化合物显示出抗增殖活性，可能特别有用于癌症的治疗。
• 이미다졸린 유도체 및 이의 중간체 제조방법
  申请人：Fusion Biotechnology 주식회사 퓨전바이오텍(120190347629) Corp. No ▼ 230111-0299832BRN ▼520-88-01078

  公开号：KR20220134934A

  公开（公告）日：2022-10-06

  본 발명은 안정성 및 효율성이 개선된 이미다졸린 유도체 제조방법 등에 관한 것으로, 본 발명의 방법은 종래 유독성이 높은 포스겐 대신 트리포스겐을 이용하여 개선된 안전성을 가지며, 원팟 반응으로 목적 생성물을 얻을 수 있으므로, 고순도, 높은 수율 및 짧은 반응시간을 가지며, 나아가 반응 완료 후 컬럼 정제가 아닌 고체 회수가 가능하여 대량생산 현장 적용에 용이한 장점이 있다.

  这项发明涉及改进稳定性和效率的伊莫达唑类化合物的制备方法。该发明的方法使用三氟化物代替传统的高毒性的氰甲烷，具有更高的安全性，可以通过单锅反应获得目标产物，具有高纯度、高收率和短反应时间的优点，此外，在反应完成后，可以直接回收固体而不需要柱层析纯化，因此非常适合大规模生产现场应用。
• NOVEL CIS-IMIDAZOLINES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1758868A1

  公开（公告）日：2007-03-07
• US7893278B2
  申请人：——

  公开号：US7893278B2

  公开（公告）日：2011-02-22